The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A10 | Drugs used in diabetes | |
| 3 | A10B | Blood glucose lowering drugs, excl. insulins | |
| 4 | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | |
| 5 | A10BK08 |
| Active Ingredient | Description | |
|---|---|---|
| Bexagliflozin |
Bexagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorption of the majority of glucose from the renal glomerular filtrate in the renal proximal tubule. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BRENZAVVY Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
